117 related articles for article (PubMed ID: 11859209)
1. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas.
Kumaki F; Kawai T; Churg A; Galateau-Sallé FB; Hasleton P; Henderson D; Roggli V; Travis WD; Cagle PT; Ferrans VJ
Am J Surg Pathol; 2002 Mar; 26(3):365-70. PubMed ID: 11859209
[TBL] [Abstract][Full Text] [Related]
2. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
3. Expression profile of telomerase subunits in human pleural mesothelioma.
Dhaene K; Wauters J; Weyn B; Timmermans JP; van Marck E
J Pathol; 2000 Jan; 190(1):80-5. PubMed ID: 10640996
[TBL] [Abstract][Full Text] [Related]
4. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
Cakir C; Gulluoglu MG; Yilmazbayhan D
Pathology; 2006 Feb; 38(1):10-5. PubMed ID: 16484001
[TBL] [Abstract][Full Text] [Related]
5. UHRF1 Immunohistochemical Staining Separates Benign Reactive Spindle Cell Mesothelial Proliferations From Sarcomatoid Mesotheliomas.
Yang H; Cheung S; Churg A
Am J Surg Pathol; 2022 Jun; 46(6):840-845. PubMed ID: 34772842
[TBL] [Abstract][Full Text] [Related]
6. Cadherins, catenins and APC in pleural malignant mesothelioma.
Abutaily AS; Collins JE; Roche WR
J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.
Ikeda S; Shibata T; Funakoshi N
Rinsho Byori; 2005 Jun; 53(6):487-93. PubMed ID: 16026073
[TBL] [Abstract][Full Text] [Related]
8. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
9. Pathological anatomy and molecular pathology.
Krismann M; Müller KM; Jaworska M; Johnen G
Lung Cancer; 2004 Aug; 45 Suppl 1():S29-33. PubMed ID: 15261430
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity in human pleural mesothelioma.
Dhaene K; Hübner R; Kumar-Singh S; Weyn B; Van Marck E
Thorax; 1998 Nov; 53(11):915-8. PubMed ID: 10193387
[TBL] [Abstract][Full Text] [Related]
11. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Derakhshan F; Ionescu D; Cheung S; Churg A
Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
[TBL] [Abstract][Full Text] [Related]
12. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
Salisbury T; Churg A
Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
Cagle PT; Truong LD; Roggli VL; Greenberg SD
Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
15. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
[TBL] [Abstract][Full Text] [Related]
19. SV40 infection induces telomerase activity in human mesothelial cells.
Foddis R; De Rienzo A; Broccoli D; Bocchetta M; Stekala E; Rizzo P; Tosolini A; Grobelny JV; Jhanwar SC; Pass HI; Testa JR; Carbone M
Oncogene; 2002 Feb; 21(9):1434-42. PubMed ID: 11857086
[TBL] [Abstract][Full Text] [Related]
20. Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.
Soini Y; Kahlos K; Puhakka A; Lakari E; Säily M; Pääkkö P; Kinnula V
Br J Cancer; 2000 Oct; 83(7):880-6. PubMed ID: 10970689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
